454482-11-2

Basic information

• Product Name: 1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE-4-BORONIC ACID PINACOL ESTER
• Synonyms: 1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE-4-BORONIC ACID PINACOL ESTER;4,4,5,5-tetramethyl-2-(1-methyl-3,5-dihydro-2H-pyrid-4-yl)-1,3,2-dioxaborolane;1-Methyl-1,2,3,6-tetrahydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine;1-Methyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine;1-Methyl-4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)piperidine;Pyridine, 1,2,3,6-tetrahydro-1-Methyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;1-Methyl-1,2,3,6-tetrahydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 2-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;1-Methyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester 97%
• CAS NO: 454482-11-2
• Molecular Formula: C₁₂H₂₂BNO₂
• Molecular Weight: 223.12
• Mol File: 454482-11-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 252.5 °C at 760 mmHg
• Flash Point: 106.5 °C
• Appearance: White to off-white/Crystalline Powder
• Density: 0.97g/cm³
• Vapor Pressure: 0.0151mmHg at 25°C
• Refractive Index: 1.467
• Storage Temp.: 2-8°C
• PKA: 9.25±0.40(Predicted)
• CAS DataBase Reference: 1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE-4-BORONIC ACID PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE-4-BORONIC ACID PINACOL ESTER(454482-11-2)
• EPA Substance Registry System: 1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE-4-BORONIC ACID PINACOL ESTER(454482-11-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 454482-11-2(Hazardous Substances Data)

Usage

Uses

1-Methyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester can be used as a substrate in the study of para-alkenylation reactions of toluene using thianthrene S-oxide and palladium catalyst.

InChI:InChI=1/C12H24BNO2/c1-11(2)12(3,4)16-13(15-11)10-6-8-14(5)9-7-10/h10H,6-9H2,1-5H3

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 180692-27-7 1-methyl-4-[(trifluoromethanesulfonyl)oxy]-1,2,3,6-tetrahydropyridine 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 50-00-0 formaldehyd 
• 375853-82-0 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine 
• 74-88-4 methyl iodide 
• 181219-01-2 4-pyridineboronic acid pinacol ester 
• 1195-66-0 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1445-73-4 1-Methyl-4-piperidone 

Downstream Products

• 1383703-45-4 5-(1-methylpiperidin-4-yl)-3-{1-[4-(morpholin-4-ylcarbonyl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazole 
• 69675-08-7 1-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine 

Relevant articles and documents

Synthesis method of N-methyl-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester

The invention belongs to the field of synthesis of medical intermediates, and particularly relates to a synthesis method of N-methyl-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester. According to the method, N-Boc-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester is selected as a raw material, Boc protection is removed under an acidic condition, paraformaldehyde, a reducing reagent and HOBt are added for an N-methylation reaction, the method can effectively inhibit the occurrence of quaternary ammonium salt side reactions, the post-treatment is simple, and the method is suitable for industrial production. The crude product is recrystallized to obtain the N-methyl-1, 2, 5, 6-tetrahydropyridine-4-boronic acid pinacol ester product with the purity of more than 98.0%, and the two-step molar yield is more than 90%.

SPIROCYCLIC COMPOUNDS

Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.